Griseofulvin: Difference between revisions
Bmurray990 (talk | contribs) |
Bmurray990 (talk | contribs) |
||
| Line 13: | Line 13: | ||
==Special Populations== | ==Special Populations== | ||
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: | *[[Drug Ratings in Pregnancy|Pregnancy Rating]]: X | ||
*[[Lactation risk categories|Lactation risk]]: | *[[Lactation risk categories|Lactation risk]]: Not recommended given potential for serious side effects. | ||
*Renal dosing: | *Renal dosing: none | ||
*Hepatic dosing: | *Hepatic dosing: none | ||
==Contraindications== | ==Contraindications== | ||
Revision as of 20:29, 26 January 2019
Administration
- Type: Antifungal
- Dosage Forms: Suspension 125mg/5ml; Tablet 125mg, 250mg, 500mg
- Routes of Administration: Oral
- Common Trade Names: Grifulvin V, Gris-PEG
Adult Dosing
- 250-1000mg PO daily
Pediatric Dosing
- 13.6-22.7kg: 125-250mg PO daily
- >22.7kg: 250-500mg PO daily
Special Populations
- Pregnancy Rating: X
- Lactation risk: Not recommended given potential for serious side effects.
- Renal dosing: none
- Hepatic dosing: none
Contraindications
- Allergy to class/drug
- Hepatocellular failure
- Porphyria
- Pregnancy
Adverse Reactions
Serious
- Acroparesthesia
Common
- Photosensitivity, rash, urticaria
- Nausea/vomiting, diarrhea
- Headache
Pharmacology
- Half-life: 9-22h
- Metabolism: Liver
- Excretion:
Mechanism of Action
- Fungistatic, deposits into keratin precursor cells and inhibits fungal mitosis